GlassScriptPhysician profile
Bradley Chastant
NPI 1770581811
$2,240.09
in general payments reported to CMS, 2019-2025
29 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $209 · 2021: $285 · 2022: $399 · 2023: $338 · 2024: $246 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $411.92 | 2020-2025 | |
| Glaxosmithkline, LLC. | $387.51 | 2019-2025 | Trelegy Ellipta, Nucala |
| Optinose US, INC. | $284.96 | 2019-2025 | |
| Allergan, INC. | $189.94 | 2019-2022 | |
| Abbvie INC. | $108.55 | 2021-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $96.33 | 2019-2024 | |
| Kaleo, INC. | $84.72 | 2019-2021 | |
| Astellas Pharma US INC | $83.32 | 2019 | |
| Acclarent, INC | $62.93 | 2019-2022 | |
| Musculoskeletal Transplant Foundation INC. | $55.47 | 2020 | |
| Itamar Medical INC | $51.09 | 2023-2024 | Watchpatone |
| Ars Pharmaceuticals Operations, INC. | $48.11 | 2025 | Neffy |
| Integra Lifesciences Corporation | $45.78 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Aerin Medical INC. | $39.83 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $34.15 | 2025 | Unithroid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $28.37 | 2020-2022 | |
| Phadia US INC. | $27.54 | 2023 | Immunocap |
| Smith+Nephew, INC. | $25.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.80 | 2019-2021 | |
| Intersect Ent, INC. | $18.11 | 2019 | |
| Ethicon US, LLC | $17.80 | 2019 | |
| Hikma Pharmaceuticals USA | $15.78 | 2022 | |
| Oyster Point Pharma, INC. | $15.69 | 2024 | Tyrvaya |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2020 | |
| Pfizer INC. | $15.13 | 2024 | |
| Lilly USA, LLC | $14.22 | 2025 | Zepbound, Mounjaro |
| Ambu INC. | $14.08 | 2020 | |
| Amgen INC. | $11.74 | 2021 | |
| Sanofi Pasteur INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Chastant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.